Transforming the Treatment of Neuromuscular Diseases
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Creating the new generation of genetic therapies
Advancing revolutionary therapies to treat degenerative neuromuscular diseases
Careers at PepGen
We’re seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)Read Press Release
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular DystrophyRead Press Release
Sorry, we couldn't find any posts. Please try a different search.